#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13328	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2039	647.0	0	.	n	.	0	A69G	SNP	69	69	A	310	310	G	779	G,T	723,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13328	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2039	647.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1691	1691	T	691	T	652	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13328	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2039	647.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1425	1425	C	806	C	760	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25118	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3695	677.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1762	1762	A	865	A,G	805,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25118	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3695	677.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2396	2396	C	814	C	760	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25118	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3695	677.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2470	2470	A	822	A	786	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25118	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3695	677.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3022	3022	C	795	C,T	743,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	1934	folP	852	852	99.77	folP.l15.c17.ctg.1	1651	116.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	915	917	AAA	177;176;177	A;A;A	172;173;174	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	1934	folP	852	852	99.77	folP.l15.c17.ctg.1	1651	116.4	0	.	p	.	0	V275M	NONSYN	823	825	GTG	1287	1289	ATG	151;154;151	A;T;G	140;143;141	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	1934	folP	852	852	99.77	folP.l15.c17.ctg.1	1651	116.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1146	1148	AGC	186;188;186	A;G;C	172;175;171	folP.WHO_X_01360c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5342	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3420	155.7	1	SNP	p	S91F	0	.	.	271	273	TCC	600	602	TCC	163;159;159	T;C;C	154;149;152	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5342	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3420	155.7	1	SNP	p	D95N	0	.	.	283	285	GAC	612	614	GAC	166;168;165	G;A;C	152;155;153	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5342	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3420	155.7	1	SNP	p	D95G	0	.	.	283	285	GAC	612	614	GAC	166;168;165	G;A;C	152;155;153	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1618	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1303	123.7	0	.	p	.	0	F178L	NONSYN	532	534	TTC	860	862	CTC	171;169;168	C;T;C	163;157;160	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1618	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1303	123.7	1	SNP	p	G45D	0	.	.	133	135	GGC	461	463	GGC	192;191;193	G,A;G;C	183,1;184;187	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	860	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1089	78.8	0	.	n	.	0	A197.	DEL	197	197	A	658	658	A	191	A	184	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4916	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3109	157.6	1	SNP	p	D86N	0	.	.	256	258	GAC	636	638	GAC	205;202;202	G;A;C	194;188;193	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4916	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3109	157.6	1	SNP	p	S87I	0	.	.	259	261	AGT	639	641	AGT	204;202;205	A;G;T	194;192;196	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4916	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3109	157.6	1	SNP	p	S87R	0	.	.	259	261	AGT	639	641	AGT	204;202;205	A;G;T	194;192;196	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4916	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3109	157.6	1	SNP	p	S87W	0	.	.	259	261	AGT	639	641	AGT	204;202;205	A;G;T	194;192;196	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4916	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3109	157.6	1	SNP	p	S88P	0	.	.	262	264	TCC	642	644	TCC	205;208;206	T;C;C	195;196;197	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4198	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2622	159.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1537	1539	GGC	211;210;209	G;G;C	200;199;196	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1361	1363	GCA	208;213;213	G;C;A	194;199;199	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1364	1366	ATC	216;216;216	A;T;C	206;204;205	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1376	1378	GTG	220;217;218	G;T;G	206;202;203	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1376	1378	GTG	220;217;218	G;T;G	206;202;203	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1880	1882	ACC	185;188;188	A;C;C	165;171;173	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1934	1936	GCG	187;187;187	G;C,G;G	167;150,1;158	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1934	1936	GCG	187;187;187	G;C,G;G	167;150,1;158	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2057	2059	GGC	168;168;167	G;G;C	157;153;156	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2066	2068	GGC	172;171;170	G;G,T;C	158;160,1;159	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3916	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2628	148.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2084	2086	CTG	160;165;161	C,G,T;T,A;G,A	124,5,1;120,1;123,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5438	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3139	172.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1608	1610	CCG	211;214;213	C,A;C;G	187,1;199;194	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2362	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1847	127.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	577	577	C	174	C	154	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	432	434	GAA	253;257;254	G;A;A	232;235;234	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	720	722	GAT	227;223;224	G;A;T	209;203;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	843	845	TCA	211;207;208	T;C;A	199;198;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	K207E	NONSYN	619	621	AAA	939	941	GAA	206;207;206	G,A;A;A	193,1;199;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	972	974	GTC	204;201;200	G,A;T;C	190,1;185;186	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	984	986	TCT	191;190;188	T,C;C;T	183,1;183;179	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1302	1304	GCA	193;191;191	G;C;A	183;180;181	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	1	SNP	p	G120K	1	.	.	358	360	AAG	678	680	AAG	233;237;234	A;A;G	219;221;220	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	1	SNP	p	A121D	1	.	.	361	363	GAC	681	683	GAC	230;228;227	G;A;C	216;211;213	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2642	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1563	167.9	1	SNP	p	D121N	0	.	.	361	363	GAC	681	683	GAC	230;228;227	G;A;C	216;211;213	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10136	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4849	208.3	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1952	1954	AAT	249;249;249	A;A;T	239;237;239	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1088	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1122	96.7	1	SNP	p	V57M	1	.	.	169	171	ATG	505	507	ATG	230;228;228	A;T;G	217;216;216	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
